Advertisement

Topics

Ablynx nv Company Profile

06:27 EDT 20th September 2018 | BioPortfolio

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies™ therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and have the potential to create new market opportunities beyond those accessible to conventional antibodies.
Since commencing operations in 2002, Ablynx has generated Nanobody™ leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.

Ablynx’s Nanobody™ technology was originally discovered at laboratories of the Free University of Brussels (VUB). Scientists at the VUB discovered that up to half of the antibody repertoire in camelidae consists of antibodies that lack a conventional antibody light-chain, but retain full antigen-binding capacity. The technology and intellectual property created around this discovery was further developed within the Flanders Interuniversity Institute for Biotechnology (VIB). In 2001 VIB created Ablynx in collaboration with founding venture investor, GIMV. Ablynx now operates from its state-of-the-art facilities in Ghent, Belgium.

Location

Technologiepark 4
Ghent
Zwijnaarde
9052
Belgium

Contact

Phone: 32 9 261.06.32
Fax: 32 9 261.06.28
Email: info@ablynx.com


News Articles [50 Associated News Articles listed on BioPortfolio]

Ablynx: ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, 17 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 Feb...

Ablynx’s Success Story: The Past, Present and Future

Fintan Walton talks to Edwin Moses, CEO of Ablynx, about the success that the company has enjoyed since its inception, and his plans for it going forward. Edwin talks about the importance of location ...

Ablynx: SANOFI AND ABLYNX ANNOUNCE THE SUCCESSFUL RESULTS OF THE INITIAL TENDER OFFER PERIOD FOR ABLYNX AND COMMENCEMENT OF SQUEEZE-OUT TENDER PERIOD

Paris, France and Ghent, Belgium - May 14, 2018 - Sanofi [Euronext: SAN; NYSE: SNY] and Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced the results of the initial tender offer period o...

Sanofi completes $3.9bn acquisition of Ablynx

Sanofi has completed the acquisition of biopharmaceutical company Ablynx for nearly $3.9bn following the expiry of the Squeeze-out procedure. The...Read More... The post Sanofi completes $3.9bn acquis...

Sanofi & Ablynx announce success of initial tender offer

Biopharmaceutical companies, Sanofi and Ablynx, have announced the successful results of the initial tender offer period for Sanofi to acquire outstanding shares of Ablynx.

Ablynx drug fails in mid-stage lupus trial

Ablynx’s vobarilizumab has failed in a mid-stage trial in lupus, with the biotech’s multi-billion buyout from Sanofi just around the corner. Vobarilizumab is an anti-IL-6R drug that Ablynx is dev...

The EMA Recommends the Approval of First Nanobody from Ablynx

Ablynx’s nanobody Cablivi is the first therapy for a rare blood disorder to receive a positive opinion from a committee of the European Medicines Agency (EMA).  Cablivi (caplacizumab) is a nan...

Ablynx's anti-inflammation drug fails in lupus

Vobarilizumab missed the primary endpoint of the mid-stage STEADY study, painting a gloomier outlook for Ablynx's opt-in deal with AbbVie.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ablynx nv

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therap...

More Information about "Ablynx nv" on BioPortfolio

We have published hundreds of Ablynx nv news stories on BioPortfolio along with dozens of Ablynx nv Clinical Trials and PubMed Articles about Ablynx nv for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ablynx nv Companies in our database. You can also find out about relevant Ablynx nv Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record